-- 
Boehringer, Eli Say Release Two-Year, Phase III Lingaliptin Data

-- B y   R a j i v   S e k h r i
-- 
2011-09-16T11:00:37Z

-- http://www.bloomberg.com/news/2011-09-16/boehringer-eli-say-release-two-year-phase-iii-lingaliptin-data.html
Boehringer Ingelheim and Eli Lilly
and Co. said a 102-week Phase III study for linagliptin showed
meaningful and durable reductions in blood glucose for adults
with type 2 diabetes.  To contact the editor responsible for this story:
Rajiv Sekhri at 
 rsekhri1@bloomberg.net  